Company intelligence / Profile preview

Diamyd Medical

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Diamyd Medical’s lead candidate, Diamyd® (recombinant GAD65/alum), is an antigen-specific immunomodulatory therapeutic aiming to preserve endogenous insulin production in individuals with recent-onset Type 1 Diabetes who carry the HLA DR3-DQ2 genotype. The pivotal Phase III trial DIAGNODE-3 is actively recruiting and an early readout is expected in March 2026. Previous studies have shown significant results for preserving insulin production in genetically defined patient groups[6][9].

Therapeutic areas: Endocrinology
Modalities: VaccineRecombinant protein
Industry: Biotech

Drug pipeline

7 assets

Diamyd

6 more assets in the full pipeline.

Request access →

Partnerships

Breakthrough T1D (formerly JDRF)Global network of clinics and academic collaborators

Beyond the preview

Go deeper on Diamyd Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diamyd Medical.

Explore the full profile